💊 ยา A-Z 🧬 เป้าหมาย 🛠 เครื่องมือ 📚 คู่มือ
ยาทั้งหมด หมวดหมู่ยา ด้านการรักษา ผลข้างเคียง
คู่มือ อภิธานศัพท์ ไทม์ไลน์
การเปรียบเทียบ เส้นทางของยา กลุ่มยา
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Zenocutuzumab

CHEMBL4298025 Phase 4 ได้รับการอนุมัติ Antibody
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Zenocutuzumab (MCLA-128) is a bispecific antibody targeting HER2 and HER3 that blocks the binding of neuregulin-1 (NRG1) to HER3, thereby inhibiting HER2-HER3 heterodimerization and downstream PI3K/AKT and MAPK signaling driven by NRG1 fusion oncoproteins. It is under investigation for NRG1 gene fusion-positive cancers, including non-small cell lung cancer, pancreatic cancer, and breast cancer, where NRG1 fusions drive constitutive HER2-HER3 pathway activation. Its mechanism is particularly relevant for the small subset of cancers harboring NRG1 rearrangements.

ด้านการรักษา

Pancreatic Cancer Non-Small Cell Lung Cancer Breast Cancer Prostate Cancer Colorectal Cancer

กลไกการออกฤทธิ์

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

Zenocutuzumab (MCLA-128) is a bispecific antibody targeting HER2 and HER3 that blocks the binding of neuregulin-1 (NRG1) to HER3, thereby inhibiting HER2-HER3 heterodimerization and downstream PI3K/AKT and MAPK signaling driven by NRG1 fusion oncoproteins. It is under investigation for NRG1 gene fusion-positive cancers, including non-small cell lung cancer, pancreatic cancer, and breast cancer, where NRG1 fusions drive constitutive HER2-HER3 pathway activation. Its mechanism is particularly relevant for the small subset of cancers harboring NRG1 rearrangements.

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Yes, Zenocutuzumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4298025. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.